146 related articles for article (PubMed ID: 29547597)
41. Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea.
Mauri G; Pedrani M; Ghezzi S; Bencardino K; Mariano S; Bonazzina E; Serra F; Pedrazzoli P; Caccialanza R; Cavestro GM; Siena S; Artale S; Sartore-Bianchi A
BMJ Support Palliat Care; 2024 Jan; 13(e3):e885-e889. PubMed ID: 37344158
[TBL] [Abstract][Full Text] [Related]
42. Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy.
Park SM; Kim YJ; Lee JY
Cancer Med; 2024 Apr; 13(7):e7142. PubMed ID: 38545845
[TBL] [Abstract][Full Text] [Related]
43. MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update.
Herrstedt J; Clark-Snow R; Ruhlmann CH; Jordan K; Scotté F
Support Care Cancer; 2023 Dec; 32(1):57. PubMed ID: 38135822
[No Abstract] [Full Text] [Related]
44. Black Race Is a Social Construct, and There Is No Biological Mechanism to Justify Differences in Antiemetic Prophylaxis.
Andreae MH; White RS
Anesth Analg; 2023 Dec; 137(6):e54-e55. PubMed ID: 37973142
[No Abstract] [Full Text] [Related]
45. Antiemetics: american society of clinical oncology clinical practice guideline update.
Basch E; Hesketh PJ; Kris MG; Prestrud AA; Temin S; Lyman GH
J Oncol Pract; 2011 Nov; 7(6):395-8. PubMed ID: 22379425
[TBL] [Abstract][Full Text] [Related]
46. Correction: An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo® in the Management of Chemotherapy-Induced Nausea and Vomiting in India.
Mv C; Thomas B; Biswas G; Gupta S; Dattatreya PS; Bhagat S; Patil S; Bhushan S; Barkate H
Cureus; 2024 Apr; 16(4):c169. PubMed ID: 38651087
[TBL] [Abstract][Full Text] [Related]
47. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
[TBL] [Abstract][Full Text] [Related]
48. Portuguese consensus on the prevention and treatment of nausea and vomiting induced by cancer treatments.
Vieira C; Bergantim R; Madureira E; Barroso JCM; Labareda M; Parreira ST; Castro A; Macedo A; Custódio S
Porto Biomed J; 2023; 8(5):e234. PubMed ID: 37846304
[TBL] [Abstract][Full Text] [Related]
49. Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride.
Ienca R; Giardiello C; Scozzarro A; di Cola RS; Di Lorenzo N; Juneja G; Lopez G; Badiuddin F
Obes Surg; 2019 Sep; 29(9):2952-2956. PubMed ID: 31104280
[TBL] [Abstract][Full Text] [Related]
50. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
51. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
[TBL] [Abstract][Full Text] [Related]
52. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
Clark-Snow RA; Vidall C; Börjeson S; Jahn P
Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
[TBL] [Abstract][Full Text] [Related]
53. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
